Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients

被引：0
|
作者：
Ava Kwong
Vivian Yvonne Shin
Cecilia Y. S. Ho
Chun Hang Au
Thomas P. Slavin
Jeffrey N. Weitzel
Tsun-Leung Chan
Edmond S. K. Ma
机构：
[1] The University of Hong Kong and University of Hong Kong-Shenzhen Hospital,Department of Surgery
[2] Hong Kong Sanatorium & Hospital,Department of Surgery
[3] Hong Kong Hereditary Breast Cancer Family Registry,Department of Pathology, Division of Molecular Pathology
[4] Hong Kong Sanatorium & Hospital,Department of Medical Oncology & Therapeutics Research, Division of Clinical Cancer Genetics
[5] City of Hope,Department of Population Sciences
[6] Beckman Research Institute of City of Hope,undefined
来源：
BMC Cancer | / 20卷
关键词：
Hereditary breast cancer; mutation; Chinese; Breast cancer risk;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
    Kwong, Ava
    Shin, Vivian Yvonne
    Ho, Cecilia Y. S.
    Au, Chun Hang
    Slavin, Thomas P.
    Weitzel, Jeffrey N.
    Chan, Tsun-Leung
    Ma, Edmond S. K.
    [J]. BMC CANCER, 2020, 20 (01)
  • [2] Germline mutations of TP53 gene in breast cancer
    Damineni, Surekha
    Rao, Vadlamudi Raghavendra
    Kumar, Satish
    Ravuri, Rajasekar Reddy
    Kagitha, Sailaja
    Dunna, Nageswara Rao
    Digumarthi, Raghunadharao
    Satti, Vishnupriya
    [J]. TUMOR BIOLOGY, 2014, 35 (09) : 9219 - 9227
  • [3] Germline mutation in TP53 gene in a cohort of 2,561 Chinese high-risk breast cancer patients using multigene panel testing
    Kwong, A.
    Shin, V.
    Au, C. H.
    Ho, C.
    Slavin, T.
    Weitzel, J.
    Chan, T. L.
    Ma, E.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [4] Enrichment and screening of LFS patients by analyzing TP53 germline mutations of a Chinese cancer cohort.
    Lu, Changyu
    Fang, Yu
    Zhou, Fachen
    Liu, Yuntong
    Niu, Hongchuan
    Li, Kai
    Ma, Tonghui
    Zhang, Xiaoyan
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [5] Clinical implications of germline mutations in breast cancer: TP53
    Katherine Schon
    Marc Tischkowitz
    [J]. Breast Cancer Research and Treatment, 2018, 167 : 417 - 423
  • [6] Clinical implications of germline mutations in breast cancer: TP53
    Schon, Katherine
    Tischkowitz, Marc
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 417 - 423
  • [7] Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer
    Sheng, Shuyan
    Xu, Ye
    Guo, Yonghai
    Yao, Lu
    Hu, Li
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (02) : 487 - 495
  • [8] TP53 germline mutation testing in early onset breast cancer
    Conte, B.
    Varesco, L.
    Iacono, G.
    Poggio, F.
    Blondeaux, E.
    Levaggi, A.
    D'Alonzo, A.
    Bighin, C.
    Giraudi, S.
    Vaglica, M.
    Pronzato, P.
    Del Mastro, L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [9] Prevalence of germline TP53 mutations in HER2+ breast cancer patients
    Michelle G. Rath
    Serena Masciari
    Rebecca Gelman
    Alexander Miron
    Penelope Miron
    Kathleen Foley
    Andrea L. Richardson
    Ian E. Krop
    Sigitas J. Verselis
    Deborah A. Dillon
    Judy E. Garber
    [J]. Breast Cancer Research and Treatment, 2013, 139 : 193 - 198
  • [10] Prevalence of germline TP53 mutations in HER2+breast cancer patients
    Rath, Michelle G.
    Masciari, Serena
    Gelman, Rebecca
    Miron, Alexander
    Miron, Penelope
    Foley, Kathleen
    Richardson, Andrea L.
    Krop, Ian E.
    Verselis, Sigitas J.
    Dillon, Deborah A.
    Garber, Judy E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (01) : 193 - 198
12345